In Korea, alcoholic liver disease (ALD) is the second most common cause of chronic liver disease after viral liver disease, and the rate of alcohol-related deaths is high, at 9.6 deaths per 100,000 persons per year. Nevertheless, the Korean culture is lenient toward drinking and the inebriated state, which is due to alcohol being considered an important social lubricant for both business and private gatherings. ALD tends to be thought of as a personal problem, and as such its importance is underestimated. Furthermore, academic interest in ADL is dwindling since the advent of antiviral therapy. However, given the keen worldwide interest and research into ALD, there remains a need for clinical practice guidelines that are tailored to the Korean healthcare system for the management of this disease. This need prompted the Korean Association for the Study of the Liver (KASL) to develop the "KASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease", based on a systematic approach to reflect evidence-based medicine and expert opinion in internal medicine and psychiatry, with the aim of setting clinical practice guidelines for the management of ALD and improving public health in Korea.

The main targets of these guidelines are patients in the Korean healthcare system with ALD or alcohol use disorder. The guidelines are intended to provide useful information and guidance to physicians, caregivers, and healthcare workers with regard to ALD diagnosis, education, and research.

The guidelines were developed based on recent studies and evidence, with key questions for each section formulated based on the PICO (Patient/Problem, Intervention, Comparison, Outcome) format. Using these key questions, a literature search was performed using MeSH terms or keywords in PubMed/MEDLINE, KoreaMed, and Korean Medical Database to collect and analyze relevant studies. Studies from the past 5 years were preferentially selected and the quality of evidence was evaluated with the aid of a categorized checklist. The decision to include or exclude a study was based on standards set by the committee.

The level of evidence and grade of recommendation were stratified according to the modified Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system (Table 1).1 "Level of evidence" refers to the level of confidence in the estimate of the effect, based on consideration of the study design and quality, and the amount, consistency, and directness of evidence. "Grade of recommendation" refers to the level of confidence associated with a recommendation, based on consideration of the quality of evidence, the balance between the desirable and undesirable effects of an intervention, the preferences, and the cost.

These guidelines were developed based on evidence-based medicine and expert opinion. However, the recommendations presented here should not be taken as inflexible standards of care that should be followed without exception. Different opinions may exist regarding the best treatment option for an individual patient.

The committee identified the following key questions to be covered in these guidelines. Current evidence and recommendations are provided for each key question.

These guidelines were reviewed by an external review board comprising 12 ALD specialists who are members of the KASL, and 1 specialist in guidelines methodology. The final manuscript was endorsed by the board of executives of the KASL.

All of the required funding was provided by the KASL. These guidelines may not be altered, modified, or distributed without the permission of the KASL.

The Korean version of the KASL Clinical Practice Guidelines for the Management of Alcoholic Liver Disease was released in July 2013 on the KASL website at http://www.kasl.org. Updates are planned when new reliable evidence is accumulated. Detailed plans for updates and revision will be posted on the KASL website.

1. Due to the recent increase in alcohol consumption in Korea, the epidemiology of ALD including its incidence and prevalence must be investigated. (B1)

1. There is a need for a nationwide study of the epidemiology of ALD in Korea.

Given that a significant portion of patients who visit primary care facilities are hazardous drinkers, the risk for many diseases due to alcohol consumption may be decreased with proper recognition and interventions that lead to abstinence or decreased drinking.26-29 The best screening test for hazardous drinkers is a questionnaire, since this has been shown to have a higher sensitivity than blood-based tests.30

While many questionnaires are available, the ones most frequently used are the CAGE (Cut down, Annoyed, Guilty, Eye-opener) questionnaire and the AUDIT questionnaire. The CAGE questionnaire is simple, being based on four yes/no questions, and while easily adoptable it has low sensitivity for hazardous drinking, the stage before alcohol use disorder (Appendix 2).28,31-35

AUDIT is a ten-item questionnaire developed by the WHO and is appropriate for most primary care settings (Appendix 3).35,36 The first three questions measure the quantitative aspects of drinking such as the quantity consumed and the drinking habit, the next three items gauge alcohol dependence, and the last four items measure the level of harmful drinking such as the psychological and social impacts. AUDIT is the most appropriate test for identifying both alcohol use disorder and hazardous drinking,37-39 with AUDIT-K being used for a Korean cohort (Appendix 4).40 The disadvantages of AUDIT include the larger number of questions and the longer time required to grade each question. Therefore, a shorter version has been developed, called AUDIT-Consumption (AUDIT-C), which employs only the first three questions regarding alcohol consumption. This has the advantage of a shorter testing time while maintaining a relatively high sensitivity and specificity.41,42 Given the limited amount of time available for outpatients in Korea, the third question of AUDIT (AUDIT-3) alone can also be used to reduce the response time, since in this version of AUDIT the third question of AUDIT regarding binge drinking is asked first, and if the answer is negative for the past 1 year, screening is ended early due to the low likelihood of that patient being a hazardous drinker; while for a positive answer, additional AUDIT questions are asked to complete the screening test.41

2. If a patient appears to be at risk of alcohol-related medical problems, a structured questionnaire, such as AUDIT, should be administered to obtain more qualitative information about a patient's alcohol consumption and problems. (A1)

3. AUDIT-K is recommended as a screening test for outpatients with alcohol use disorder; alternatively, AUDIT-C or AUDIT-3 may be used for convenient testing. (B1)

1. There is a need to assess the prevalence of ALD in patients with alcohol use disorder.

Alcoholic fatty liver, also known as alcoholic steatosis, is the initial presentation of liver injury due to chronic alcohol consumption. Fatty liver is the most common disease associated with alcohol use, and is seen in 80-90% of heavy drinkers.52 While full recovery is possible with abstinence at this stage, one study found that continued alcohol use (≥400 g/week) increased the risk of progression to cirrhosis in 30% of cases, and to fibrosis or cirrhosis in 37%.53 However, significant liver injury may still occur in individuals who drink less. Once alcoholic fatty liver develops, it is not clear whether it will remain a fatty liver or progress to a more severe liver disease. Comorbidities due to environmental and genetic factors, viral hepatitis, obesity, and HIV infection may convert alcoholic fatty liver into steatohepatitis.

Alcoholic hepatitis (also known as alcoholic steatohepatitis), which is usually accompanied by fatty liver disease includes a broad spectrum of pathological processes. Symptomatic patients present with advanced liver disease, with concomitant cirrhosis in more than 50% of them.54 The prognosis is even worse with severe alcoholic hepatitis, with a 1-month mortality of 40%.55 Drink excessively, may induce recurrent episodes of alcoholic hepatitis in patients with ALD, and if this is severe or associated with liver cirrhosis, complications occur due to liver failure and portal hypertension, leading to a high short-term mortality. In addition, long-term follow-up of these patients has shown that they rarely improve, instead usually remaining with alcoholic hepatitis or progressing to liver cirrhosis.56 Liver fibrosis is common in alcoholic hepatitis and is accelerated in the presence of chronic alcoholic hepatitis.57 Even in patients with fatty liver or steatohepatitis but without liver fibrosis, 38-56% will eventually progress to liver cirrhosis with continued alcohol consumption.58-61

Long-term excessive drinking results in a 15-30% lifetime risk of alcoholic liver cirrhosis.52,53,62 At the time of diagnosis of alcoholic liver cirrhosis it is accompanied by no complications in 24% of patients, ascites alone in 55%, variceal bleeding alone in 6%, combined ascites and variceal bleeding in 4%, and hepatic encephalopathy in 11%.63 In a patient initially presenting without complications, ascites (12%), variceal bleeding (6%), and hepatic encephalopathy (4%) may appear as a first complication within 1 year of diagnosis.63 The rate of decompensation within 1 year of a diagnosis is 37.6% with alcoholic liver cirrhosis, compared to 25.2% in non-alcoholic liver cirrhosis.64

As in other diseases, alcoholic liver cirrhosis may lead to decompensated liver cirrhosis and is associated with a risk of developing HCC.65 The incidence of HCC is 7.2-16.0% in alcoholic liver cirrhosis, with a 1% annual risk in patients with decompensated alcoholic liver cirrhosis.61,66-69 Viral hepatitis plays a significant role in the development of HCC in chronic drinkers.70

The overall risk of death in patients with alcoholic liver cirrhosis is 5-30 times higher in alcoholics than in the general population.61,71 For advanced alcoholic liver cirrhosis the median survival time is 1-2 years and the 5-year survival rate is 23-50%, which is worse than that for non-alcoholic liver cirrhosis.72 In compensated alcoholic liver cirrhosis, the 5-year survival rate approaches 90% with abstinence but decreases to less than 70% with continued drinking.61,73 In decompensated alcoholic liver cirrhosis the 5-year survival rate is 60% with abstinence and 30% with continued drinking.74 The median survival time for decompensated alcoholic liver cirrhosis is 61 months,75 and 80% of patients who continue drinking even in the presence of ascites will die within 7 months.76 The 1-year mortality rate is 17% among patients with liver cirrhosis but without any complications, while this increases to 20-64% if complications develop, in which case the 5-year mortality rate approaches 58-85%.48,63

1. There is a need to elucidate the natural history of ALD.

A standard drink is sometimes used as a unit measure to estimate the quantity of alcohol consumed, and it varies markedly between countries; in Korea it corresponds to 12 g of pure alcohol. The risk of ALD substantially increases in both sexes when alcohol consumption exceeds 30 g/day.52 An increased risk of liver injury with alcohol consumption exceeding 30 g/day was found in the large-scale Dionysos cohort study performed in northern Italy.77,78 There are also other reports of a proportional relationship between the quantity of alcohol consumed and the risk of ALD. The minimum amount of alcohol required for liver cirrhosis is 20-40 g/day in men and 10-20 g/day in women, and most retrospective studies also show that the risk of liver injury is increased when alcohol consumption exceeds 40-80 g/day.79-84 Many prospective studies have found a proportional relationship between the quantity of alcohol consumed and the presence of alcoholic liver injury.50,85,86 According to the USA guidelines for non-alcoholic fatty liver disease, significant alcohol consumption has been defined in the past 2 years as exceeding 21 standard drinks per week in men and 14 standard drinks per week in women.87,88

In conclusion, there is a quantity dependent relationship between the amount of alcohol consumed and the risk of ALD. Although most prospective and retrospective studies demonstrate that the prevalence of liver injury increases in proportion to the daily alcohol intake, this relationship does not always hold, suggesting that other factors, such as genetic predisposition, can also be involved.89,90

ALD is seen more frequently in daily drinkers than in intermittent drinkers.50,78,91 Binge drinking, a form of drinking habit that has recently surfaced as a social problem in many countries, is defined as consuming more than five drinks for men and four drinks for women over a time period of 2 hours (Table 2).83 This consumption of a large amount of alcohol over a short period of time is associated with the development of ALD.92,93 The risk of ALD is also increased with habits such as drinking without meals, drinking at multiple locations at a time, mixing drinks, and initiating alcohol drinking at a younger age.52,94

While few studies have investigated the association between type of alcohol and liver injury, the available data suggest that liver injury is associated more strongly with the total quantity of alcohol consumed than with the type of alcohol. A notable finding is that small amounts of wine reportedly decrease mortality rates associated with both cardiovascular and non-cardiovascular disease, including liver disease.95,96 However, there is still controversy regarding the association between the type of alcohol consumed and the risk of liver injury, especially for liver cirrhosis.

The frequency of liver injury is higher among women than men, even when the same quantity of alcohol is consumed. Many studies have found that the incidence of alcoholic liver injury is higher in women than in men with a daily alcohol consumption of 30-80 g.85,97,98 Liver injury occurs more easily in women, including over shorter time periods or involving smaller quantities of alcohol.99,100 The relatively safe level of alcohol consumption in women has been reported as less than 10-20 g.59,81,86,97,101 In a large prospective study, the risk of developing ALD with a weekly alcohol consumption of 336-492 g differed significantly between men (7.0) and women (17.0).97 The risk of liver cirrhosis was dramatically increased in women with a daily alcohol intake exceeding 40 g.79,99,101 The blood alcohol concentration is higher in women than in men after consuming the same amount of alcohol, resulting in a higher risk of ALD.102 Women exhibit a decreased level of alcohol dehydrogenase (ADH) in the stomach, resulting in a slower first step of alcohol metabolism, increased bioavailability of alcohol, and increased risk of liver injury.98 In addition, factors such as a lower body distribution of alcohol due to a higher body fat content and an estrogen-induced increase in oxidative stress and inflammation contribute to the increased risk of ALD in women.103

There may be an association between ethnicity and the risk of alcoholic liver injury.104 The frequency of alcoholic liver cirrhosis is higher in African-American and Latin-American men than in white men, and the death rate for this condition is the highest among Latin-American men.105 These differences seem to be independent of the quantity of alcohol consumed.106

Protein-calorie malnutrition is a common clinical manifestation of ALD.107 The degree of malnutrition is known to be strongly correlated with the development of complications such as ascites, hepatic encephalopathy, and hepatorenal syndrome, and a gradual increase in mortality.108 ALD is accompanied by deficiencies in micronutrients such as folate, thiamine, pyridoxine, vitamin A, vitamin E, zinc, and magnesium, and such deficiencies in folate, vitamin E, and zinc may accelerate liver disease.109,110

Obesity increases the severity of alcohol-induced liver injury.111 The relationship between obesity and alcohol consumption differs between men and women.112,113 In obese persons, excessive drinking leads to increased risks of liver disease,114,115 liver cirrhosis, and mortality.116-118 High body mass index and fasting glucose are independent risk factors for the progression of liver fibrosis even after correcting for the amount of alcohol consumed and the duration of alcohol abuse,119 which is thought to be due to insulin resistance and hyperinsulinemia.120 Therefore, obesity is an important risk factor for liver cirrhosis in the presence of excessive drinking.119,121

Concomitant alcoholic liver cirrhosis is seen three times as frequently in monozygotic twins than in dizygotic twins, suggesting a genetic susceptibility in ALD.89 Several family studies have also suggested an association between alcohol dependence and genetic factors.122,123

Genetic polymorphisms in enzymes involved in alcohol metabolism, such as ADH2, ADH3, and aldehyde dehyrogenase 2 (ALDH2), are related to alcohol dependence and ALD.124 The ALDH2*2 allele produces an ALDH2 variant with greatly reduced enzymatic activity and delayed aldehyde metabolism, and a lower risk of developing alcohol addiction; a meta-analysis of data related to Asian populations found that the presence of the ALDH2*2 allele was associated with a lower frequency of alcohol dependence and ALD.125 The frequency of the ALDH2*2 allele was significantly lower among Korean patients with alcoholic liver cirrhosis than among those without it.126,127 Mutation of the gene encoding patatin-like phospholipase domain-containing protein 3 (PNPLA3) has been suggested as a genetic risk factor for ALD, with a higher frequency of PNPLA3 rs738409 GG found in a high-risk group for progression to ALD.128 Two recent meta-analyses have provided evidence of an association between genetic polymorphisms in the gene encoding interleukin (IL)-10 and alcoholism,129 and an increased risk of ALD among alcoholics with allelic variants of the gene encoding glutathione-S-transferase.130 However, these candidate genes have not been confirmed in Korean studies. Studies of ALD have thus far been limited to identifying specific genetic mutations, indicating a need for genome-wide association analyses.

The prevalence of hepatitis C virus (HCV) is higher among alcoholics than non-alcoholics, and the combination of HCV and alcohol has a synergistic effect on liver injury.131 Possible underlying mechanisms for this include immune suppression, stimulation of viral replication, increased oxidative stress, and hepatocyte cytoxicity. Alcohol intake by patients with HCV infection increases the risk of liver cirrhosis and HCC,132,133 and reduces their responses to interferon treatment.134

Unlike for HCV, data is limited regarding the association between hepatitis B virus (HBV) and progression of liver disease due to alcohol consumption. Nevertheless, alcohol consumption does have an adverse effect on hepatitis patients.135 Specifically, alcohol directly affects host-cell metabolism and gene expression, which acts to increase the expression and replication of viral genes.136 Therefore, patients with HBV should avoid consuming alcohol.97

Smoking is a risk factor for ALD, causes oxidative stress, and accelerates fibrosis in patients with ALD.137 Abstaining from smoking is therefore recommended in patients with ALD.

Many studies have found that the risk of ALD reduces as coffee consumption increases, and that coffee may suppress the development of ALD.138-141 A marked decrease in mortality due to liver disease was found among those who drink three or more cups of coffee per day compared to those who drink two or fewer cups per day.142 The consumption of caffeinated drinks other than coffee is not associated with a decreased incidence of liver cirrhosis, which suggests that substances other than caffein in coffee have an important role in ALD.140

4. Excessive drinking, defined as an average alcohol consumption exceeding 40 g/day in men and 20 g/day in women, increases the risk of alcoholic liver injury and should be avoided. (A1)

5. Daily or binge drinking increases the risk of ALD and should be avoided. (A1)

6. Alcohol abstinence is necessary for patients with chronic viral hepatitis. (B1)

7. Obesity and smoking increase ALD, and so weight control and smoking cessation are recommended. (B1)

1. There is a need to characterize cases of ALD that are accompanied by other liver diseases such as viral hepatitis.

2. There is a need to assess the interactions between the risk factors for ALD.

3. There is a need for genome-wide association studies involving patients with ALD.

Steatosis is the initial reaction to alcohol abuse and is characterized by the adiposis of hepatocytes. Alcoholic fatty liver occurs through many complex mechanisms, via the following four steps.144 First, alcohol oxidation leads to increases in the synthesis of nicotinamide adenine dinucleotide (NADH), triglycerides, and fatty acids, and to the suppression of mitochondrial β-oxidation.145 Second, there is an increase in the influx of free fatty acids from the adipose tissue and chylomicrons from the visceral mucosa into the liver.145 Third, ethanol mediates the suppression of adenosine-monophosphate-activated protein kinase (AMPK) activation, resulting in an increase in lipid biosynthesis, suppression of peroxisome proliferator-activated receptor α (PPARα), and decrease in lipolysis due to the activation of sterol regulatory element binding protein 1c (SREBP1c).146-148 Fourth, there is acetaldehyde-induced mitochondria and microtubule damage, resulting in decreased NADH oxidation and accumulation of very-low-density lipoprotein (VLDL).145

Steatohepatitis is defined as a condition with fatty liver, inflammatory cell infiltration comprising mainly polymorphonuclear leukocytes, and hepatocyte injury. In ALD, although alcoholic steatohepatitis is a necessary step in the progression to liver fibrosis and cirrhosis, liver fibrosis is not included in the definition of steatohepatitis.43 Currently, there is no consensus on the pathologic classification of steatohepatitis, and the severity of this condition is determined by environmental factors such as the quantity of alcohol consumed, lifestyle, and dietary habits.43

Various factors affect the onset of alcoholic steatohepatitis. First, the toxic effect of acetaldehyde and the production of oxygen free radicals affect the development of this condition. Ethanol is metabolized into acetaldehyde by ADH within the cytosol, P450 within the microsomes, and catalase within the peroxisomes. Ethanol metabolism results in the production of oxygen free radicals, peroxidation of lipids, and a decrease in mitochondrial glutathione and S-adenosyl-L-methionine (SAMe) levels, and these metabolites sensitize the hepatocyte to injury. Acetaldehyde is then metabolized by mitochondrial ADH into acetate, which combines with protein and DNA to alter their function, ultimately affecting protein synthesis.149,150 These products then act as auto-antigens to activate the immune system, increasing the lymphocyte count and causing liver injury. Furthermore, acetaldehyde causes oxidative stress and apoptosis through mitochondrial damage and impairment of glutathione function.151

Second, there are pro-inflammatory cytokines. Alcohol metabolites and oxygen free radicals stimulate the signal-transduction pathways related to nuclear factor-κB (NFκB), signal transducer and activator of transcription-Janus kinase (STAT-JAK), and c-Jun N-terminal kinase (JNK), which induce the production of inflammation mediators such as tumor necrosis factor-α (TNF-α), IL-17, CXC chemokines, and osteopontin.152 Alcohol abuse disrupts the normal intestinal microbiota and increases the permeability of the endotoxins produced by intestinal bacteria, increasing serum lipopolysaccharide levels,153 and causing an inflammatory reaction in Kupffer cells via the CD14/toll-like receptor 4 (TLR 4) pathway.154 This inflammatory environment in ALD causes the infiltration of polymorphonuclear leukocytes, production of oxygen free radicals, and hepatocyte injury.

Liver fibrosis is a recovery response seen in every form of chronic liver injury, and is characterized by the excessive accumulation of extracellular matrix proteins such as collagen.155,156 Fibrosis can occur in alcoholic steatohepatitis, and occurs mainly where ADH is located, typically in pericentral and perisinusoidal regions.155 In the progression stage, collagen bands become apparent and bridging fibrosis develops. This stage precedes liver cirrhosis and the formation of regeneration nodules. The cytological and molecular biological mechanism of fibrosis in ALD is currently not well understood.120

Metabolites of alcohol such as acetaldehyde directly activate hepatic stellate cells (HSCs), the main producers of collagen in the injured liver, and play a major role in the production of portal fibroblasts and bone-marrow-derived myofibroblasts.155,156 HSCs are also activated by injured hepatocytes, activated Kupffer cells, and infiltration of polymorphonuclear leukocytes. These cells secrete growth factors such as transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor (PDGF), cytokines such as leptin, angiotensin II, IL-8, and TNF-α, soluble mediators such as nitric oxide, and oxygen free radicals. Importantly, oxygen free radicals stimulate the signaling pathway within HSCs, which includes extracellular signal-regulated kinase, phosphoinositide 3 kinase (PI3K)/Akt, and JNK.157 These oxygen free radicals also enhance the activity of tissue inhibitor of metalloproteinase 1, reducing the activity of metalloproteinases and stimulating the accumulation of extracellular matrix proteins such as collagen.

1. There is a need to study how genetic differences influence the progression of liver fibrosis.

The type of alcoholic beverage, quantity of alcohol consumed, weekly drinking frequency, and duration of drinking are all important data to obtain during history-taking. Since patients frequently deny or underreport the amount of drinking, it is helpful to obtain the drinking history through questionnaires or from family members. Although currently there is no consensus on the minimum amount of alcohol required for ALD, a cutoff that is often applied is an average alcohol intake exceeding 40 g/day in men and 20 g/day in women.97,158-160 The average daily alcohol intake is calculated using the following equation: [amount consumed (mL)×alcohol by volume (%)×specific gravity of alcohol (0.785)×number of drinking days per week]÷7. For example, if a person drinks one Soju bottle (360 mL, 19% alcohol by volume) three times a week, then the amount consumed would be (360 mL×19%×0.785)÷100=53.7 g, and the average daily alcohol intake would be (53.7 g×3)÷7=23 g. The alcohol contents of various forms of alcoholic beverage are listed in Table 3.

A standard drink in Korea contains 12 g of alcohol (as defined by the Ministry of Health and Welfare), and so is approximately equal to 1.5 nips of Soju (90 mL), 1 can of beer (355 mL), 1 bowl of Makgeolli (230 mL), 1 glass of wine (120 mL), or 1 nip of whisky (40 mL).

The effects of ALD can range from being asymptomatic to liver failure and death. While symptoms and signs such as epigastric discomfort, fever, fatigue, anorexia, malaise, weight loss, tender hepatomegaly, jaundice, spider angiomata, cachexia, gynecogenic changes, and right upper-quadrant abdominal bruit may occur, they are nonspecific.160-162 In severe alcoholic hepatitis or liver cirrhosis, symptoms and signs such as ascites, lower extremity edema, hepatic encephalopathy, and esophageal variceal bleeding may be seen.163 Damage to organs other than the liver may manifest as gastritis, peptic ulcer, pancreatitis, neuropathy, myopathy, Dupuytren's contracture, cardiomyopathy, arrhythmia, anemia, parotid gland hypertrophy, lacrimal gland hypertrophy, altered mental status due to delirium tremens, and sleep disorders.164-169

Blood tests for detecting a history of chronic alcohol consumption include serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltranspeptidase (GGT), mean corpuscular volume (MCV), and carbohydrate deficient transferrin (CDT).170-172 Combining the results of several of these tests is superior to using any single test.173 In ALD, AST elevation is more prominent than that of ALT, but the levels of AST and ALT usually do not exceed 300 IU/L. Alcoholic hepatitis may be suspected when the AST/ALT ratio exceeds 2,174,175 and has a very high probability when it exceeds 3.176 Because GGT is elevated by alcohol consumption in about 75% of habitual drinkers, it is useful to determine whether a patient with ALD has indeed abstained from drinking.177,178 However, care must be exercised since GGT may also be elevated due to non-alcoholic liver disease, obesity, diabetes, smoking, or drug use.179,180 In general, GGT levels recover slowly following abstinence from alcohol. MCV may also be elevated by heavy drinking, and is occasionally observed when the daily alcohol consumption exceeds 60 g.181,182 While MCV elevation alone has a low sensitivity, this is increased when accompanied by GGT elevation or when the levels decrease following treatment;183 MCV returns to normal after several months of abstinence.184 While CDT is known as a useful biochemical marker for heavy drinking,170,171,185,186 it is not a popular measure due to its high specificity but low sensitivity.187 Other findings seen with progression of liver disease include a decrease in serum albumin, increase in bilirubin, prolonged prothrombin time, and decrease in platelet count.

Radiologic tests can be used to identify steatosis, evaluate the progression of liver disease and the presence of complications, and rule out diseases such as biliary tract disease and liver tumors.188 However, radiologic tests alone cannot be used for the definitive diagnosis of alcohol as the cause of liver disease. Ultrasonography is useful for identifying steatosis, and findings such as liver morphology and splenomegaly can be used to evaluate the progression of liver disease.189 Although abdominal computed tomography (CT) scans and magnetic resonance imaging (MRI) are more accurate than ultrasonography for evaluating steatosis, there currently are no standardized test protocols and these methods are costly.190,191 Liver elastography may be used to indirectly evaluate the degree of fibrosis in ALD. This test is based on the correlation between liver stiffness due to fibrosis and liver elasticity, and employs ultrasonography or MRI.192-194 While these tests have the advantage of being noninvasive, they are also non-standardized and care must be exercised when interpreting the results since the presence of steatosis and severe inflammation may interfere with correct interpretations.

The diagnosis of ALD may be made in patients with a daily alcohol consumption exceeding 40 g in men and 20 g in women, with clinical, laboratory, radiological, or histological evidence of liver disease, and in whom other etiologies for liver injury can be excluded. Although excluding other etiologies of liver disease such as viral hepatitis, non-alcoholic fatty liver disease, and drug-induced liver injury is helpful for diagnosing ALD, because it is possible that more than one etiology is present, it is important to identify which is the main lesion. ALD is categorized based on the underlying pathology into alcoholic fatty liver, alcoholic hepatitis, and alcoholic liver cirrhosis (Table 4).206 While exclusive forms do exist, overlapping clinical features are seen in most cases.

Alcoholic fatty liver is usually asymptomatic. In blood tests, AST, ALT, or bilirubin levels may be normal or mildly elevated.160 While these values typically return to normal following several weeks of alcohol abstinence,195 in some cases the disease may progress to liver fibrosis or cirrhosis.50

Alcoholic hepatitis presents with various clinical features. In mild cases it is difficult to distinguish alcoholic hepatitis from alcoholic fatty liver, while in severe cases alcoholic hepatitis carries a high risk of death due to liver failure. Liver fibrosis may lead to portal hypertension, making it difficult to distinguish it from liver cirrhosis.163 Blood tests may reveal anemia, leukocytosis, and thrombocytopenia, and the AST/ALT ratio typically exceeds 2.175,176,207 While these clinical features usually resolve following abstinence, they may last more than 6 months in severe alcoholic hepatitis.

Alcoholic liver cirrhosis and liver cirrhosis due to other etiologies share similar clinical features.208 While it is not uncommon to be asymptomatic, anorexia and malnutrition due to habitual drinking can result in weight loss and skeletal muscle atrophy. Progression of liver cirrhosis may cause spider angioma, gynecomastia, and jaundice, and portal hypertension may result in variceal bleeding, ascites, and hepatic encephalopathy. Even in alcoholic liver cirrhosis, alcohol abstinence and proper nutrition can result in improved clinical features.48

8. Thorough history-taking for details such as the amount, frequency, duration, and type of drinking is necessary to make a diagnosis of ALD. (A1)

9. With adequate history of excessive drinking and clinical evidence for liver disease, the diagnosis of ALD can be made. In patients with severe alcoholic hepatitis requiring corticosteroid treatment, a liver biopsy should be considered for both a definitive diagnosis and estimation of prognosis. (B1)

1. There is a need to evaluate the usefulness of a liver biopsy in ALD.

2. There is a need for standardized histological criteria for the classification and evaluation of the severity of ALD.

3. There is a need to develop noninvasive diagnostic methods for ALD.

10. The mDF score and the MELD score are useful for determining the prognosis and guiding treatment in patients with alcoholic hepatitis. (A1)

1. There is a need for clinical models that predict poor prognosis among patients with an mDF score of <32.

AWS refers to the group of symptoms and signs that occur 6-24 hours following the abrupt cessation of alcohol consumption among those who habitually drink excessively. Symptoms and signs include those of autonomic nervous system activation such as tachycardia, sweating, and hand tremor, gastrointestinal symptoms such as nausea and vomiting, and if severe, deficits in cognitive function such as hallucinations, seizures, and withdrawal delirium that may lead to death. Alcohol withdrawal seizure is a rebound phenomenon that can occur following the abrupt cessation of alcohol consumption that is due to a lowered seizure threshold. Because there is no need for anticonvulsants in patients with alcohol withdrawal seizure, it is necessary to distinguish it from genuine seizure. Delirium tremens is a serious complication of AWS, typical symptoms of which include altered mental status, disorientation to person, place, or time, and intra- and inter-daily variations of symptoms.227 The symptoms are typically worst at 3-5 days following the abrupt cessation of alcohol consumption. Signs of autonomic nervous system activation such as high fever, tachycardia, hypertension, and sweating, as well as comorbidities such as dehydration, electrolyte imbalance, renal failure, head trauma, infection, gastrointestinal bleeding, pancreatitis, and liver failure should be carefully and strictly evaluated, and frequent monitoring of vital signs is necessary.228

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) is known to be helpful for evaluating the severity of AWS, treatment planning, and facilitating objective communication between healthcare providers. However, high scores may be seen in psychiatric conditions that are similar to AWS, such as anxiolytic withdrawal, anxiety disorder, and physical conditions such as sepsis, hepatic encephalopathy, and severe pain.228 For this reason, the CIWA protocol is not recommended for a diagnosis of AWS.228

A comparison of inpatient versus outpatient treatment revealed that outpatient treatment was more cost-effective, but there was no difference in the alcohol abstinence rate at 6 months.229 If there are serious complications of AWS such as delirium, seizures, or physical and/or psychological comorbidities, admission and inpatient treatment is recommended, with treatment goals of symptomatic relief without complications and maintenance of abstinence as a long-term treatment. Therefore, psychiatric consultation is recommended for the evaluation and acute management of AWS and long-term abstinence planning.

For pharmacological treatment, long-acting benzodiazepines (e.g., chlordiazepoxide and diazepam) are recommended for the prevention of seizures, with effects such as anxiety relief, sedation, and somnolence via activation of gamma-aminobutyric acid (GABA).230 Lorazepam, which is an intermediate-acting benzodiazepine, is recommended for patients with severe AWS, advanced age, recent head trauma, liver failure, respiratory failure, other serious medical comorbidities, or obesity. Lorazepam is started at a dosage of 6-12 mg/day and tapered off following resolution of the withdrawal symptoms (Table 6).231,232

Diminished cognitive function due to thiamine deficiency is common in patients with alcohol use disorder; thiamine should thus be given to all patients with AWS (100-300 mg/day) and maintained for 2-3 months following resolution of their withdrawal symptoms.233

11. For AWS, psychiatric consultation is recommended for the evaluation, treatment, and long-term planning of alcohol abstinence. (A1)

12. Inpatient treatment is recommended for cases with serious complications such as alcohol withdrawal delirium or seizures. (A1)

13. Benzodiazepines should be used to treat AWS. (A1)

While many drugs have been used to promote alcohol abstinence among patients with alcohol use disorder, the use of these agents is limited to those with liver-function abnormalities (liver-function tests: >3×normal increase in bilirubin) or renal failure. There are few studies that target ALD patients with the exception of baclofen. More studies are required to obtain evidence of their efficacy and safety in patients with ALD.

Baclofen is a GABAB receptor agonist that is used as a muscle relaxant.238 A study involving patients with liver cirrhosis found that a 12-week course of baclofen effectively maintained abstinence by reducing the craving for alcohol.239 Further studies should investigate the use of baclofen for abstinence in patients with ALD.240,241

Acamprosate reduces the withdrawal effects of and the craving for alcohol. The desired concentration for acamprosate is reached within 1-2 weeks of initiating treatment and it is effective at maintaining abstinence in alcohol-dependent patients following withdrawal.242,243 Treatment is initiated 3-7 days following the last episode of alcohol consumption and started after withdrawal symptoms have resolved. With respect to dosage, 1,998 mg/day is given to patients with a body weight of ≥60 kg and decreased by a one-third for those with a body weight of <60 kg, for a total treatment period of 3-6 months.244-246

Naltrexone decreases the concentration of dopamine in the brain and dampens activation of the reward pathway by alcohol, thereby decreasing excessive drinking and recurrence rates and increasing abstinence duration in patients with alcohol dependence.247,248 With respect to dosage, 25 mg is given during the first 1-3 days and increased to 50 mg thereafter, with a typical total treatment period of 3-6 months, but this can also last for up to 12 months.249 Because there is risk of toxic liver injury, naltrexone is not recommended in patients with ALD.

Disulfiram is an inhibitor of ALDH that causes a buildup of acetaldehyde in the body following alcohol consumption.250 Since the buildup of acetaldehyde results in unpleasant symptoms such as flushing, dizziness, nausea, vomiting, arrhythmia, dyspnea, and headache, it is known as an aversive therapy and is currently not commonly used.

The goal of psychosocial treatment is to allow the patient to understand and obtain insight into his or her pathological pattern of drinking. Active psychological support should be provided with focus on the environment, reasons, and expected consequences of drinking, and should be accompanied by family and group therapy as well.251,252

The aim of individual psychotherapy for a patient with alcohol dependence is to establish a therapeutic plan by careful psychiatric evaluation and select treatment modalities such as individual interview, psychoeducation, group therapy, and cognitive behavioral therapy. The treatment principles of alcohol dependence involve (1) allowing the patient to accept his or her lack of control over alcohol, (2) providing education regarding alcohol dependence, and (3) helping the patient to achieve control over him- or herself in order to maintain abstinence. This sort of treatment should not end as part of inpatient treatment, but instead should be continued after discharge to prevent recurrence. It is therefore important that patients with alcohol dependence actively get involved in group therapy such as Alcoholics Anonymous. This group meets on a nationwide basis and makes it possible to reduce the craving for alcohol and maintain healthy abstinence through peer support.

Social support from family and friends is also necessary for successful therapy. Alcohol dependence is a dysfunctional family disorder, in that in many cases it is not only the patient who needs treatment but also family members who are subject to abuse from the patient. Both the patient and his or her family may benefit from active involvement in family education and therapy. Community alcohol counseling centers provide regular abstinence meetings, family meetings, and psychoeducation; coordination with these facilities may prove very helpful.

Other methods of psychosocial treatment include motivational enhancement, 12-step facilitation therapy, cognitive behavioral therapy, social skills training, and coping skills training. Behavioral therapy involves training the patient to use methods other than alcohol to alleviate anxiety, and includes interventions such as relaxation therapy and assertive training. Psychiatric consultation is recommended for psychosocial treatment.

Brief interventions are effective methods that involve providing pertinent evaluation, information, and advice to reduce risky drinking behavior and risk of ALD.253 Commonly used brief interventions include motivational interviewing and counseling over a short time span. A brief intervention is delivered in a structured fashion, among which the FRAMES (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) model is representative. The FRAMES method involves feedback about the dangers of continued drinking, emphasizes the drinker's responsibility in assuming the choices and consequences of drinking, advises abstinence, provides a menu of alternatives, empathizes with the drinker's perspective, and encourages self-motivation for abstinence.254-256 Brief interventions have been reported to lower morbidity and mortality related to drinking, and to be an effective non-pharmacologic approach for abstinence.256,257 Brief interventions may be implemented in various healthcare settings, such as the inpatient or outpatient setting, private clinic, or public healthcare settings such as community counseling centers, or even healthcare services in the workplace and universities. It is a cost-effective method at a primary medical institution and is effective in patients with mild ALD.253,258

14. In patients with ALD, alcohol abstinence is the most important treatment. (A1)

15. In patients with ALD, pharmacologic and psychosocial treatment can be implemented to achieve alcohol abstinence. (B2)

16. In patients with ALD, baclofen and acamprosate can be used to achieve alcohol abstinence. (B2)

17. In hazardous drinkers and patients with alcohol use disorder, brief interventions should be implemented to encourage abstinence or controlled drinking. (A1)

1. There is a need to evaluate the efficacy of combined therapy of baclofen and psychosocial therapy for alcohol abstinence in ALD.

2. There is a need to identify effective brief intervention methods.

3. There is a need to evaluate the efficacy and safety of naltrexone and acamprosate in ALD.

4. There is a need to evaluate new pharmacologic treatments for abstinence in ALD.

18. Active and sufficient nutritional support should be provided to patients with ALD. If three meals per day do not provide adequate nutrition, additional meals in the early morning and late at night can help restore nutritional balance. (B1)

19. Vitamin and mineral supplementation should be provided along with nutritional therapy to patients with ALD. (B1)

Alcohol abstinence is the most important treatment for alcoholic hepatitis,57 and should be administered as described above.

Most patients with severe alcoholic hepatitis are malnourished. Although several studies have shown that enteral nutrition improves the survival rate irrespective of steroid treatment, it is still not clear whether nutritional therapy is effective in treating severe alcoholic hepatitis.263,272

Corticosteroids (prednisolone 40 mg/day for 28 days) are the most commonly recommended treatment for severe alcoholic hepatitis. They are thought to act by reducing the transcription of pro-inflammatory cytokines such as TNF-α. In patients with histologically confirmed severe alcoholic hepatitis, serum levels of TNF-α and intercellular adhesion molecule-1 (ICAM-1) were shown to decrease with steroid treatment, and the degree of change in the soluble form of ICAM-1 was found to be correlated with the degree of histological improvement.273

Indications for treatment with steroids are the presence of severe alcoholic hepatitis with a poor prognosis. Various prognosis prediction models such as mDF, MELD, and GAHS can be used to determine which patients should take steroids. Scores of mDF score ≥32, MELD >21, or GAHS ≥9, or hepatic encephalopathy are commonly used indications. Steroids are usually contraindicated in those with gastrointestinal bleeding, renal failure, pancreatitis, or uncontrolled infection.

Steroid treatment for alcoholic hepatitis has been investigated in many randomized controlled trials, and conflicting results were obtained in early clinical studies and meta-analyses.55,210,274-278 While a Cochrane review of 15 studies found no survival benefit from steroids,278 a subgroup analysis involving only "low-bias risk" studies revealed a survival benefit from steroids in patients with an mDF score of ≥32 or with hepatic encephalopathy.278 An analysis involving pooled data found that the 28-day survival rate was higher in the steroid group (84.6%) than in the placebo group (65.1%; P=0.001).277 That finding was recently confirmed in a study using data from the five recent randomized controlled trials (28-day survival rate: treatment group, 80.0%; placebo group, 65.7%; P=0.0005).210 Therefore, steroids should be useful in patients with an mDF score of ≥32.

ECBL and the Lille model were recently introduced to predict prognosis based on the response to steroid treatment (Table 5). ECBL is defined when the bilirubin level at 7 days of treatment is lower than that on the first day of treatment. One study found that the 6-month survival rate was 82% in severe alcoholic hepatitis patients with confirmed ECBL but only 23% in those without ECBL.224 The Lille model is an improved model that includes ECBL as well as several additional variables. The probability of death is scored from 0 to 1 in the Lille model, and the 6-month survival rate was 25% in those patients with a score of >0.45, which is significantly lower than that of 85% for those with a Lille score of <0.45.226 In a more recent study, patients were subdivided according to the percentile distribution of the Lille scores (≤35th, 35th-70th, and ≥70th percentiles), and classified as complete responders (≤0.16), partial responders (0.16-0.56), and null responders (≥0.56); the 28-day survival rate differed significantly between these groups, at 91.1%, 79.4%, and 53.3%, respectively.210 Given that infection occurs more frequently in patients who do not respond to steroid treatment than in those who do respond, it would be reasonable to discontinue steroids if the patient is thought to be a null responder based on ECBL or the Lille model.279 The survival rate in these patients may be significantly higher after liver transplantation than when continuing with medical treatment only.280 However, a social consensus is needed on this issue.

In conclusion, treatment with steroids is effective in patients with mDF scores of ≥32. However, if ECBL is not observed or the Lille score is ≥0.56, steroids should be discontinued and other rescue therapies such as liver transplantation should be considered (Fig. 3).210,224,226

Pentoxifylline, given at a dose of 400 mg three times daily for 28 days, may be tried as an alternative to steroids for treating severe alcoholic hepatitis.281 Pentoxifylline is a selective phosphodiesterase inhibitor that increases intracellular cAMP levels, which in turn decrease the expression of cytokines such as TNF-α, IL-8, and macrophage inflammatory protein-1a.282 Pentoxifylline may be used in patients with infection or renal failure. A study involving 101 patients with severe alcoholic hepatitis found that the 28-day mortality rate was significantly lower in the pentoxifylline group (24.5%) than in the placebo group (46.1%).281 Given that the percentage of deaths due to hepatorenal syndrome was 50% (6 of 12 patients) in the pentoxifylline group and 92% (22 of 24 patients) in the placebo group, it appears that the increase in survival rate may be due to a decrease in the incidence of hepatorenal syndrome.281

A randomized comparative study of pentoxifylline and steroids found that the death rate was lower in the pentoxifylline group.283 However, that study involved only a small group of patients, and the survival rate in the steroid group was far lower than that reported previously, thereby questioning the validity and acceptability of the conclusion. Another randomized controlled trial comparing the efficacies of pentoxifylline and corticosteroids in treating severe alcoholic hepatitis was recently performed in Korea. The 1-month survival rate of patients receiving pentoxifylline was 74.5%, compared to 87.0% in those receiving prednisolone. Although the trial was intended to assess the non-inferiority of pentoxifylline compared to corticosteroids, the observed efficacy of pentoxifylline was not statistically equivalent to that of corticosteroids, supporting corticosteroids as a preferred option for severe alcoholic hepatitis.284

It is currently unclear whether combination therapy of steroids and pentoxifylline is superior to monotherapy with either agent. A recent study found no survival benefit at 4 weeks or 6 months with combination therapy of steroids and pentoxifylline.285 Therefore, combination therapy is not recommended at present.

The efficacy of early switching to pentoxifylline in steroid non-responders has been investigated by either switching patients without ECBL to pentoxifylline or continuing them on steroids;286 the 2-month survival rates did not differ between the two groups, at 35.5% and 31.0%, respectively. Pentoxifylline is therefore not recommended as a rescue therapy since steroid non-responders do not seem to obtain any benefit from an early switch to this drug.

In spite of these limitations, pentoxifylline is considered an effective alternative agent to steroids in the treatment of severe alcoholic hepatitis and improves survival rate.287

Several anti-TNF-α agents have been tested as treatments for alcoholic hepatitis under the assumption that clinical improvement may be seen by blocking TNF-α, a major cytokine involved in alcoholic hepatitis. A pilot study demonstrated the efficacy of combination therapy of infliximab and steroids.288 However, the mortality rate was found to be higher with combination therapy in a follow-up study, and therefore infliximab is currently not recommended for the treatment of severe alcoholic hepatitis.289 Treatment with etanercept was also associated with a higher 6-month mortality rate, mainly due to higher rates of serious infections compared to the placebo group.290 Therefore, anti-TNF-α agents are currently not recommended for the treatment of alcoholic hepatitis.

N-acetylcysteine has not yet been found to be effective as a treatment for alcoholic hepatitis.291 A recent trial of combination therapy with N-acetylcysteine and steroids found an increase in the short-term survival rate but no improvement in the long-term survival rate.292 Specifically, the 1-month mortality rate was lower in the combination therapy group (8%) than in the steroid-only group (24%), but the 3-month and 6-month survival rates did not differ significantly between the two groups. Interestingly, the number of deaths due to hepatorenal syndrome was lower in the combination therapy group (9%) than in the steroid-only group (22%).292 Further research is needed to evaluate the efficacy of N-acetylcysteine.

20. Alcohol abstinence is the single most important treatment for improving survival in alcoholic hepatitis. (A1)

21. Treatment with steroids is needed for patients with severe alcoholic hepatitis who have an mDF score of ≥32. (A1)

22. During steroid treatment it is important to identify patients with a high mortality risk based on ECBL or the Lille score, where rescue therapy such as liver transplantation may be considered. (B1)

23. Pentoxifylline is an alternative treatment agent to steroids that can improve the survival rate in patients with severe alcoholic hepatitis. (B1)

1. There is a need for new drugs that may be combined with steroids or pentoxifylline to increase the therapeutic efficacy in the treatment of severe alcoholic hepatitis.

2. There is a need to identify clinical factors that respond to steroids or pentoxifylline in the treatment of severe alcoholic hepatitis.

24. Liver transplantation should be considered in patients with decompensated liver cirrhosis. (A1)

25. Early liver transplantation may be considered in patients with severe alcoholic hepatitis who do not respond to medical treatment. (A2)

1. There is a need to determine the appropriate timeline for liver transplantation with regard to abstinence from alcohol in patients with ALD.

Histologic findings of central hypoxia due to thyroid hormone can occur in ALD, raising the question of whether propylthiouracil (PTU) would be effective in reducing pericentral hypoxia and cellular damage by suppressing metabolic activation due to ethanol. Some studies have found that PTU improves the mortality rate by suppressing hypermetabolic activation.323,324 However, a Cochrane meta-analysis of 6 studies involving 710 ALD patients that compared PTU versus placebo found no clear improvement in liver histology or in the liver-related or overall mortality rate.325,326

Colchicine affects liver fibrosis by suppressing collagen production, activating collagenase activity, and suppressing collagen transcellular trafficking. It has also been found to contribute to the production of cytokines that stimulate fibroblast proliferation. As such, colchicine has been investigated as a treatment agent for ALD. Clinical studies involving patients with alcoholic liver cirrhosis found that colchicine exhibited anti-inflammatory and anti-fibrotic effects,327,328 and had a positive effect on survival.329 However, subsequent controlled trials produced conflicting results, and a meta-analysis of 15 randomized trials involving 1,714 patients with ALD found no clear association between colchicine and liver function or histologic improvement, or liver-related or overall mortality.330 Therefore, considering its side effects, colchicine is not recommended for treatment of ALD.

Polyunsaturated lecithin (PUL) is a cell membrane component found in soybean extract. While its mechanism of action is unclear, it is thought to act by modulating collagenase activity.331 A study involving baboons with alcoholic liver damage found that PUL caused histologic improvement in the liver and decreased the activation of hepatic stellate cells.332 However, there was no clear association between polyenylphosphatidylcholine and progression of liver fibrosis in a follow-up randomized controlled study.333 Since PUL is a component of normal cells with a favorable side effect profile, this agent should be investigated further.

SAMe is a methyl-group donor that is involved in the biosynthesis of glutathione, a major intracellular antioxidant. A clinical study found that SAMe improved survival in both CTP class A and B patients compared to the placebo group. Although some studies have found that SAMe has treatment value in ALD, a meta-analysis found SAMe to exert no statistically significant effects on overall mortality,334,335 liver-related mortality, complications, or liver transplantation results.336,337

Metadoxine antioxidant therapy has been approved for the treatment of ALD in several countries. A large randomized controlled trial involving 136 patients with fatty liver that compared a 3-month course of metadoxine (1,500 mg/day) with placebo found meaningful improvements in liver function in both groups but with a faster recovery course in the metadoxine group.338 The persistence of fatty liver as visualized by ultrasonography was significantly decreased in the metadoxine group relative to the placebo group (28% vs. 70%). These positive effects were more noticeable in patients who had abstained from alcohol than in those who had continued to drink. However, the clinical implications remain unclear, and metadoxine is therefore not recommended for the treatment of ALD. Further research is needed to investigate the effects of metadoxine.

One randomized controlled trial has found that combination therapy with the angiotensin II receptor antagonist candesartan and ursodeoxycholic acid effects a greater histologic improvement than monotherapy with ursodeoxycholic acid.339

Anti-cytokine treatment has been proposed based on the effect of cytokines on liver fibrosis and cirrhosis.340 Although there are reports of anti-inflammatory effects of thalidomide, misoprostol, adiponectin, and probiotic agents, more evidence is needed before these agents should be used as treatments for ALD.341-343

Silymarin, a milk thistle extract with activating and anti-oxidative properties, has been evaluated in many studies as a potential treatment agent for ALD.344,345 Although one study found that silymarin contributes to improved survival, this result has not been confirmed for ALD patients in meta-analyses such as the Cochrane review.344,346

1. There are isolated reports that PTU, colchicine, PUL, SAMe, metadoxine, and silymarin affect the prognosis of ALD patients, but these have not been confirmed. There is a need to investigate new pharmacologic agents.

26. There is a need to increase public attention towards the harmful use of alcohol, and specific strategies such as limiting the accessibility of alcohol, price controls, and banning alcohol-related advertisements should be implemented. (A1)